Trial Profile

A Phase 3 program of Zygel in children and adolescents in patients with 22q deletion syndrome

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 28 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cannabidiol (Primary)
Indications DiGeorge syndrome
Focus Adverse reactions; Therapeutic Use
Sponsors Zynerba Pharmaceuticals

Most Recent Events

25 Feb 2025 According to a Harmony Biosciences media release, trial to initiate in 2025.
22 May 2023 New trial record
15 May 2023 According to a Zynerba Pharmaceuticals media release, company expect continued dialogue with the U.S. Food and Drug Administration (FDA) in 2023 regarding an acceptable trial design for a Phase 3 program in patients with 22q deletion syndrome, with the goal of finalizing a trial design by the end of 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com